STIMSTIMHealthcare · Medical Devices

STIM Stock Forecast: Neuronetics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.25
+0.81% on the day

The median 12-month analyst price target for Neuronetics, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 64 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$123.5M
Ticker Nerd rank
64/ 100
Median analyst target
$6.00
Analysts covering
5
Revenue$41.6M+9.1% y/y
Operating income−$1.5M
Net income−$3.4M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.1%
1M
−36.9%
YTD
−9.4%
1Y
−3.8%
From 52W high
−62.1%
From 52W low
+5.9%
$1.18
$3.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Neuronetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
64/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Accruals
87
Revisions
71
Issuance
51
Quality
45
Value
25
Momentum
19
Volatility
16

Growth (96): Sales and profits are climbing, and climbing faster than before.

Volatility (16): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

STIM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STIM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26STIMHigh $7.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$5.00
Low
$6.00
Median
$7.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Nov 2026William BlairInitiatesOutperform—
6 Nov 2026B. Riley SecuritiesMaintainsBuy$5.00 → $6.00
17 Sept 2026BTIGReiteratesBuy$6.00
11 Sept 2026B. Riley SecuritiesInitiatesBuy$5.00
9 Sept 2026BTIGReiteratesBuy$6.00
11 Aug 2026BTIGMaintainsBuy$5.00 → $6.00
20 July 2026BTIGInitiatesBuy$5.00
19 Mar 2026Canaccord GenuityMaintainsBuy$7.00 → $3.00
6 Aug 2025Canaccord GenuityMaintainsBuy—
5 Mar 2025Canaccord GenuityMaintainsBuy—
5 Mar 2025Citizens Capital MarketsMaintainsMarket Outperform—
14 Aug 2024JMP SecuritiesMaintainsMarket Outperform—
13 Aug 2024Canaccord GenuityMaintainsBuy—
12 Aug 2024William BlairDowngradeMarket Perform—
14 May 2024William BlairUpgradeOutperform—
6 Mar 2024Piper SandlerReiteratesOverweight—
10 May 2023JMP SecuritiesReiteratesMarket Outperform—
8 Mar 2023Canaccord GenuityMaintainsBuy—
8 Mar 2023JMP SecuritiesReiteratesMarket Outperform—
14 Oct 2021JMP SecuritiesMaintainsMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STIM.

Market Radar

This page is one stock. Monday covers all of them.

STIM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

STIM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Neuronetics, Inc. returned −3.8% against +6.9% for the S&P 500, dividends included.

STIM vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26STIMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STIM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.8×

Cheaper than 71% of US stocks

Price / book
5.3×

Cheaper than 17% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
12.5%

Higher than 59% of US stocks

Earnings growth (YoY)
—
Gross margin
51.1%

Higher than 63% of US stocks

Operating margin
−9.1%

Higher than 27% of US stocks

Net margin
—
Returns & dividend
Return on equity
−85.6%

Higher than 15% of US stocks

Return on assets
−6.6%

Higher than 30% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neuronetics, Inc. has a market value of $123.5M and an enterprise value of $168.8M.

  • Revenue in the twelve months to 30 June 2026: $155.1M. The latest quarter grew 9.1% year on year.

  • Net income over the same four quarters: −$30.8M, a −19.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.44.

  • Free cash flow in the twelve months to 30 June 2026: −$11.3M.

  • Shares outstanding: 76.2M.

  • Neuronetics, Inc. employs 658 people — $236K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

STIM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
STIMNeuronetics, Inc.$123.5M64
QTRXQuanterix Corp.$92.3M53
CATXPerspective Therapeutics, Inc.$91.0M11
APYXApyx Medical Corp.$101.1M76
OWLTOwlet, Inc.$85.0M27
LUNGPulmonx Corp.$111.9M87
LUCDLucid Diagnostics, Inc.$75.7M36

Take a look at STIM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Neuronetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about STIM

What is the STIM stock price forecast for 2026-2027?

The median 12-month analyst price target for Neuronetics, Inc. is $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STIM stock a buy right now?

Of the 5 analysts covering Neuronetics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neuronetics, Inc. 64 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STIM?

As at 21 Nov 2026, Neuronetics, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will STIM stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $6, and Ticker Nerd's factor model ranks Neuronetics, Inc. 64 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STIM stock forecast for 2030?

No analyst covering Neuronetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STIM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.

How has STIM stock performed over the past year?

Neuronetics, Inc. returned -3.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neuronetics, Inc. do?

Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder.

Company

About Neuronetics, Inc.

Neuronetics Inc. is a commercial-stage medical technology company focused on non-invasive neurohealth treatments. Its core offering is the NeuroStar Advanced Therapy System, an office-based transcranial magnetic stimulation platform used primarily for adult patients with major depressive disorder. The company also provides related treatment sessions and support services, serving psychiatric practices and mental health providers in the United States and international markets. Neuronetics operates at the intersection of medical devices and clinic services, combining device commercialization with patient care delivery. Its products are designed to expand access to non-drug therapeutic options for psychiatric and neurological conditions, making the company a significant participant in the neuromodulation market.

CEO Mr. Daniel L. Reuvers · 658 employees · United States · https://neurostar.com/neuronetics